Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems a...(the United States. Schedule of Events...),Health

Schedule of Events

Sunday, October 21 (all times are ET)

-- TAXUS ARRIVE data. Two-year follow-up data and sub-group analysis from

the TAXUS ARRIVE registry will be presented by John M. Lasala, M.D.,

PhD, at the DES Summit at 1:19 p.m. in Ballroom C of the Washington

Convention Center. The ARRIVE program is designed to collect and

analyze "real-world" safety and clinical outcomes data from the TAXUS

Express2 Paclitaxel-Eluting Stent System in the treatment of patients

with coronary artery disease. The Company plans to issue a press

release at this time.

Monday, October 22

-- Spirit III Clinical Trial Results -- XIENCE V (PROMUS) Stent and TAXUS

Stent. At 12:15 p.m., one-year data from Abbott's Spirit III Clinical

Trial will be presented by Gregg W. Stone, M.D., at a late-breaking

trial session in the main arena. Dr. Stone will provide an updated

analysis of 1,002 patients treated with the XIENCE V (PROMUS) Stent or

the TAXUS Express Stent. SPIRIT III is a large-scale, randomized,

non-inferiority, U.S. pivotal trial. The Company plans to issue a

press release at this time.

-- TAXUS ATLAS Small Vessels and Long Lesions studies. Nine-month data

from the TAXUS ATLAS global, multi-center studies will be presented at

a late-breaking trial session by the study's co-principal investigator

Mark A. Turco, M.D., at 1:00 p.m. in the main arena. Dr. Turco will

present clinical and angiographic follow-up data on patients treated

with the TAXUS Liberte 2.25 mm stent in small vessels (from the TAXUS

ATLAS Small Vessel study) and the TAXUS Liberte 38 mm stent in long

lesions (from the TAXUS ATLAS Long Lesion study). The Company plans to

issue a press release at this time.

-- TAXUS V de novo results. The Company
'/>"/>